Recruiting

NAD Supplementation

Sponsor:

University of Oklahoma

Code:

NCT05483465

Conditions

Aging

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Accepted

Interventions

Nicotinamide riboside

Placebo

Study Details

Brief summary:

Daily consumption of one of the forms of Vitamin B3, the Nicotinamide Riboside (NR), energizes the body and combats cellular aging. This study is designed to test whether NR can also improve brain health and memory.

Conditions

Aging

Study ID

NCT05483465

Start date

May 3, 2023

Status verified date

Mar, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Age ≥60 and ≤85 years of age
  • Adequate hearing and visual acuity to participate in the examinations
  • Ability to read and write in English
  • Competence to provide informed consent.
  • Mini-Mental State Exam score ≥24

Exclusion Criteria:

  • Vision or hearing impairment that would impair the ability to complete study assessments
  • Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer
  • Cerebrovascular accident other than TIA within 60 days prior to Visit 0
  • Major psychiatric disease, including major depression not currently controlled on medications, alcohol or drug abuse
  • Abnormal kidney function (creatinine >2mg/dL or EGFR <30mL/min) by most recent labs within 6 months prior to Visit 0
  • Elevated liver enzymes (AST and/or ALT above x2 upper limit of normal) by most recent labs within 6 months prior to Visit 0
  • Treatment with other NAD enhancers (Nicotinamide riboside or nicotinamide mononucleotide) within 4 weeks prior to randomization.
  • Any other medical condition which, in the opinion of investigator, would render the patient inappropriate or too unstable to complete the study protocol

Study Design

Enrollment

214 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: NR

Treatment with oral NR (1g/day per os for 8 weeks)

placebo comparator: Control

Visually identical placebo (daily, per os, for 8 weeks)

Interventions

Nicotinamide riboside

Oral NR, 1g/day per os for 8 weeks

Placebo

Visually identical pill to NR, daily per os for 8 weeks

Primary outcome measure

  • Change in neurovascular coupling using functional near infrared spectroscopy (fNIRS) [ Time Frame: 8 weeks ]
  • Change in neurovascular coupling using transcranial Doppler [ Time Frame: 8 weeks ]
  • Change in neurovascular coupling using the dynamic retinal vessel analysis [ Time Frame: 8 weeks ]
  • Change in neuronal activity [ Time Frame: 8 weeks ]

Central Contacts and Locations

Central contacts

Andriy Yabluchanskiy, MD, PhD

405-271-7622andriy-yabluchanskiy@ouhsc.edu

Locations

University of Oklahoma Health Sciences Center

Recruiting

Oklahoma City, Oklahoma, United States, 73117

Contacts

Andriy Yabluchanskiy, MD, PhD

405-271-8130andriy-yabluchanskiy@ouhsc.edu

Peter Mukli, MD, PhD

405-271-8000peter-mukli@ouhsc.edu

More Information

Sponsor

University of Oklahoma

Last update posted

Apr 1, 2026

Last verified

Mar, 2026

Keywords

  • NAD
  • NR
  • nicotinamide riboside
  • neurovascular coupling
  • endothelial function
  • cognitive function

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Oklahoma on 2026-04-01.